Decreased plasma arachidonic acid binding capacity in neonates.
Arachidonic acid (AA) metabolites have been implicated in neonatal pathologic states such as respiratory distress syndrome (RDS). Since free (nonprotein bound) AA is the substrate for synthesis of these compounds, a decreased capacity to bind AA in neonatal plasma could contribute to these disorders. AA binding was assayed by equilibrium dialysis in plasma samples from healthy adults and various infant groups. Plasma from these infant groups bound significantly less AA than adult plasma. Premature infants with RDS and premature infants receiving intralipid had the lowest capacity to bind AA. The increased availability of free AA may be important in neonatal pathophysiologic states involving arachidonate metabolites.
D000328:Adult; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000097:blood*; D005217:Fat Emulsions, Intravenous / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn / Q000097:blood*; D007234:Infant, Premature / Q000097:blood; D007567:Jaundice, Neonatal / Q000097:blood; D011485:Protein Binding; D012127:Respiratory Distress Syndrome, Newborn / Q000097:blood; D012709:Serum Albumin / Q000378:metabolism
D001095:Arachidonic Acids; D005217:Fat Emulsions, Intravenous; D012709:Serum Albumin; D016718:Arachidonic Acid